This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, Y. S.
Right arrow Articles by Täuber, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, Y. S.
Right arrow Articles by Täuber, M. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3325-3327, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus

Young S. Kim, Quingxiang Liu, Lucien L. Chow, Henry F. Chambers,* and Martin G. Täuber

Infectious Diseases Laboratory, San Francisco General Hospital, and Departments of Medicine and Neurology, University of California, San Francisco, San Francisco, California 94143-0811

Received 26 May 1998/Returned for modification 9 July 1998/Accepted 23 September 1998

The new fluoroquinolone trovafloxacin was tested against a ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus strain in the rabbit model of endocarditis. Trovafloxacin was more effective than vancomycin (CFU/g of vegetation, 2.65 ± 1.87 versus 4.54 ± 2.80 [mean ± standard deviation]; P < 0.05) or ampicillin-sulbactam plus rifampin (4.9 ± 1.1 CFU/g). The addition of ampicillin-sulbactam to trovafloxacin tended to reduce titers further.

* Corresponding author. Mailing address: Infectious Diseases Laboratory/SFGH, Box 0811, 3rd and Parnassus Ave., San Francisco, CA 94143-0811. Phone: (415) 206-5437. Fax: (415) 206-6015. E-mail: chipc{at}itsa.ucsf.edu.

Antimicrobial Agents and Chemotherapy, December 1998, p. 3325-3327, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P. (2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 46: 1503-1509 [Abstract] [Full Text]  
  • Boucher, H. W., Thauvin-Eliopoulos, C., Loebenberg, D., Eliopoulos, G. M. (2001). In Vivo Activity of Evernimicin (SCH 27899) against Methicillin-Resistant Staphylococcus aureus in Experimental Infective Endocarditis. Antimicrob. Agents Chemother. 45: 208-211 [Abstract] [Full Text]  
  • Backo, M., Gaenger, E., Burkart, A., Chai, Y. L., Bayer, A. S. (1999). Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam. Antimicrob. Agents Chemother. 43: 2565-2568 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»